CP-x Synthetic Cannabinoids Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 57 studies associated with CP-x Synthetic Cannabinoids.
Here is a small sampling of CP-x Synthetic Cannabinoids studies by title:
- THC Regulates Tearing via Cannabinoid CB1 Receptors
- Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: impact of drug and fixed-dose ratio
- Chronic Adolescent Δ9-Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment
- Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation.
- Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model.
Components of the CP-x Synthetic Cannabinoids Research Dashboard
- Top medical conditions associated with CP-x Synthetic Cannabinoids
- Proven effects in clinical trials for CP-x Synthetic Cannabinoids
- Receptors associated with CP-x Synthetic Cannabinoids
- Individual study details for CP-x Synthetic Cannabinoids
Ready to become a subscriber? Go to our PRICING page.
Page Quick Links
Select New Cannabinoid
Overview - CP-x Synthetic Cannabinoids
Description of CP-x Synthetic Cannabinoids
The CP class of synthetic cannabinoids are named after the company Carl Pfizer where they were first synthesized. For instance, CP-55,940 was discovered in 1974.Other Names:
CP Family Synthetic Cannabinoids LevonantradolCP-x Synthetic Cannabinoids Properties and Effects
Binds with PPAR-Gamma and initiates anti-inflammatory response, Binds with GPR55CP-x Synthetic Cannabinoids Receptor Binding
Strong affinity for CB1 with a mean Kd at 2.5nM (10 times more potent than THC). Very strong affinity for CB2 with a mean Kd at 0.92nM (38 times more potent than THC)Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.